The aim of the trial is to establish whether pravastatin will lead to a significant reduction of circulating anti-angiogenic factors in women with early-onset pre-eclampsia. To test this hypothesis, we will ask the following questions: 1. Does pravastatin cause a greater inhibition of circulating anti-angiogenic factors in women with early-onset pre-eclampsia compared with placebo? 2. Are there any beneficial or adverse clinical effects to the mother or the baby following gestational exposure to pravastatin? 3. If pravastatin appears to safely inhibit circulatating anti-angiogenic factors, how best can a substantive trial/health technology assessment be undertaken to develop guidance for routine use of statins to prevent or ameliorate pre-eclampsia?